Currently, there are 57.53M common shares owned by the public and among those 55.19M shares have been available to trade.
The company’s stock has a 5-day price change of 6.89% and -22.79% over the past three months. VNDA shares are trading 13.98% year to date (YTD), with the 12-month market performance up to 10.83% higher. It has a 12-month low price of $3.30 and touched a high of $6.75 over the same period. VNDA has an average intraday trading volume of 552.92K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.23%, -3.41%, and -0.47% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Vanda Pharmaceuticals Inc (NASDAQ: VNDA) shares accounts for 75.02% of the company’s 57.53M shares outstanding.
It has a market capitalization of $280.37M and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$0.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.88% over the week and 4.22% over the month.
Earnings per share for the fiscal year are expected to decrease by -1300.00%, and 155.21% over the next financial year. EPS should grow at an annualized rate of 36.10% over the next five years, compared to -37.98% over the past 5-year period.
Looking at the support for the VNDA, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on July 11, 2024, with the firm’s price target at $11. Jefferies coverage for the Vanda Pharmaceuticals Inc (VNDA) stock in a research note released on February 25, 2022 offered a Hold rating with a price target of $12. BofA Securities was of a view on May 12, 2021 that the stock is Buy, while Citigroup gave the stock Neutral rating on January 14, 2021, issuing a price target of $14. Citigroup on their part issued Buy rating on October 29, 2020.
